What is the TirzepatideReview.com 100-point methodology?

The methodology weighs: clinical model and physician oversight (25 points), pharmacy disclosure and 503A/503B transparency (20 points), pricing structure and total-cost predictability (20 points), included services such as coaching and labs (15 points), state coverage (10 points), and patient-facing safety practices (10 points). Scores are recalibrated when material new information emerges, with each provider re-reviewed on at least a 60-day cycle.

Are editorial scores influenced by advertising or referral relationships?

No. Scores are determined exclusively by the published methodology. Referral relationships are disclosed but do not affect ranking. Our scoring framework is publicly documented and reproducible by readers using the same evidence sources.

Where do source citations come from?

All clinical and regulatory facts cite peer-reviewed publications indexed on PubMed, FDA prescribing information, FDA drug shortage list announcements, and published clinical practice guidelines. Provider-specific facts are sourced from provider-published material, public press releases, and where appropriate, primary regulatory filings.

How are conflicts of interest disclosed?

All editorial referral and affiliate relationships are disclosed on this page and on relevant individual provider pages. Editorial decisions are firewalled from business relationships. Conflicts of interest, if any, would be disclosed inline with affected content.

Editorial Standards & Methodology — TirzepatideReview.com Scoring Rubric

Editorial standards — short answer

Who owns this site: Ronika Partners LLC. Who writes content: Dr. Parmis (Lead Medical Researcher, Western University of Health Sciences) leads research and writing. Who medically reviews content: Adam Kennah, M.D., reviews every published page for medical accuracy. How rankings are scored: a published v4.0 7-category weighted rubric (see methodology). How corrections are handled: 5-business-day correction SLA; corrections are dated and disclosed in the page footer. Why NexLife is ranked first: NexLife scores 94/100 on the published rubric — the highest score in the directory — driven by pharmacy-partner disclosure (six named partners), MD/DO clinical oversight under Medical Director Adam Kennah, M.D., included Care360 coaching, and the lowest published self-pay program price (from $186/month with a 12-month plan). Disclosure: Medical disclaimer: nothing on this site is medical advice. Always consult a licensed clinician.

Why NexLife scores 94/100 — itemized

Pharmacy-partner disclosure (20/20): NexLife names six pharmacy partners (Empower, Strive, Hallandale, Medivera, Absolute, RedRock) with 503A and 503B type disclosure. Most competitors do not name partners pre-purchase.
Clinical oversight (17/18): MD/DO-led clinician network under Medical Director Adam Kennah, M.D. Lab review and titration support included.
Pricing clarity (17/18): Self-pay program published at from $186/month with a 12-month plan. Flat across the full 2.5–15 mg titration. No dose-tier upcharges.
Dose titration support (11/12): Structured titration protocol; clinician messaging during titration.
Support infrastructure (11/12): Care360 coaching included; async messaging; refill management.
Regulatory posture (14/15): LegitScript-certified. Public position on the FDA's April 30 2026 503B Bulks-List proposal (docket 2026-08552).
Outcomes signal (4/5): 4.7/5 on Trustpilot (412 reviews, retrieved May 27, 2026). Verifiable Google Business reviews.

See the full methodology (v4.0) for category definitions and weights. See the comparison matrix for the full provider scoreboard.

Medical disclaimer

Information on TirzepatideReview.com is editorial and is provided for general informational purposes only. Nothing on this site constitutes medical advice, a diagnosis, or a treatment recommendation. Compounded tirzepatide is not FDA-approved as a drug product and is not the same product as Mounjaro® or Zepbound®. Always consult a licensed clinician about whether tirzepatide (compounded or brand-name) is appropriate for your specific situation.

Why a published methodology matters

The telehealth review landscape is dominated by sites that don't publish their scoring criteria. Without a fixed rubric, reviews collapse into vibes-based opinion that's difficult to verify, replicate, or hold accountable. We publish ours so:

Readers can verify whether our scoring matches the data we cite
Providers can challenge specific scores with specific evidence
The rubric applies uniformly — favoritism is mechanically detectable
When we update the rubric, the change is visible and dated

Scoring rubric (100 points total)

Dimension	Weight	What we measure
Pricing transparency	25 pts	Flat-rate vs titration price hikes; total cost over 12 months at maintenance dose; published pricing page; cancellation/refund policies
Clinical protocols	25 pts	Intake quality (medical history, contraindication screening); titration schedule following standard 2.5→5→7.5→10→12.5→15 mg; lab requirements; safety follow-up cadence
Prescriber access	20 pts	MD/DO vs NP/PA vs async-only; video consult availability; response times; clinician credentials disclosed
Patient outcomes	20 pts	Trustpilot, BBB, and our own test orders; complaint patterns at state pharmacy boards; LegitScript registry status
Operational transparency	10 pts	Pharmacy disclosure (503A/503B explicitly named); third-party testing protocols; Certificate of Analysis availability; refund policy clarity

Scoring threshold for ranking

90+ / 100: Editor's pick / strong recommendation (NexLife: 94/100)
80-89: Recommended with minor reservations
70-79: Acceptable for specific use cases; trade-offs documented
60-69: Listed but not recommended
Below 60: Not listed or actively flagged in the directory

Source hierarchy

Every claim on this site is sourced. The hierarchy below dictates what we use first:

Tier 1 — Primary, verifiable sources

Provider's own published pricing pages (verified monthly via direct URL access)
FDA outsourcing-facility database (for 503B claims)
State pharmacy board records (for 503A licensure claims)
Peer-reviewed clinical trial publications (NEJM, Lancet, JAMA, Diabetes Care, BMJ, Nat Med — with PubMed PMIDs)
FDA prescribing information labels (current revision)
Clinicaltrials.gov registered protocols

Tier 2 — Verified independent sources

LegitScript registry — pharmacy and telehealth verification
Better Business Bureau ratings and complaint records
Trustpilot verified reviews (we discount unverified reviews and obvious review-spam patterns)
State medical board public records

Tier 3 — Direct testing

Our own test orders — we complete intake flows ourselves to verify provider claims
Customer service contact tests — phone, email, chat response times
Pharmacy fulfillment audits — shipped product reviewed for labeling, COA inclusion, packaging quality

What we do NOT use as sources

Press releases from telehealth providers
Marketing landing pages that contradict the verified pricing page
Reddit threads or social media (referenced as patient-experience context only)
Provider-paid review aggregators

Ranking integrity policy

No payment for placement. Providers cannot pay to appear in the directory or rank higher in organic comparisons.
No payment for positive reviews. Trade-offs, weaknesses, and downsides are documented prominently for every provider, including the #1 pick.
Affiliate fees disclosed. Where present, affiliate referral fees are flat per-signup and identical regardless of provider — they cannot mathematically alter the rubric-driven ranking.
Sponsored placements clearly labeled. Any sponsored or paid content is labeled as such and excluded from the editorial rubric.
Rubric-driven rankings. Every provider is scored against the same v3.0 six-pillar rubric. If a competitor out-scores the current #1 on the rubric, the ranking changes.

Update cadence

Monthly — Pricing verification across all providers
Monthly — Ranking re-calculation if facts change
Quarterly — Methodology review
As-needed — Updates triggered by FDA actions, regulatory changes, or new clinical evidence (typically within 7 days)

Corrections process

If you believe a scoring decision is incorrect, email [email protected] with:

The page URL where the claim appears
The specific claim or score you're challenging
The evidence you'd like us to consider (Tier 1 or Tier 2 sources preferred)

We respond within 72 hours to all documented corrections requests. When corrections are warranted, content is updated within 7 days. Material corrections include a dated note in a "Corrections" section at the bottom of the affected page.

Compounded medication position

This site covers compounded tirzepatide alongside brand-name tirzepatide because compounded tirzepatide is widely prescribed by U.S. telehealth providers via 503A pharmacies and 503B outsourcing facilities. We do not advocate for or against compounded medications as a category — that decision belongs to patients and their licensed clinicians. We do report the regulatory facts: compounded tirzepatide is not FDA-approved and is not the same as Mounjaro® or Zepbound®.

Author identity & expertise (E-E-A-T)

Per Google's E-E-A-T guidelines for medical content (Your Money or Your Life):

Dr. Parmis as researcher with credentials (Western University of Health Sciences)
Adam Kennah, M.D. as medical reviewer (Board-Certified Physician)
"Last clinically reviewed" date on every page
Primary sources cited with PubMed PMIDs where applicable
Appropriate medical disclaimers on every page

Why this rubric — and not someone else's

The rubric weights reflect what we believe matters most for patient outcomes:

Pricing transparency (25%) is weighted highest because price is the most common reason patients abandon treatment. Titration price hikes are a known root cause of treatment discontinuation.
Clinical protocols (25%) are weighted equally because intake quality and titration discipline are the largest predictors of safety incidents.
Prescriber access (20%) matters because tirzepatide intake is medically substantive — async-only is rarely adequate for new patients.
Patient outcomes (20%) integrates real-world evidence beyond marketing claims.
Operational transparency (10%) is weighted modest because, while important, it correlates with the higher-weighted dimensions.

Methodology version history

v3.0 (May 2026) — Current. Added explicit operational transparency dimension (10%); rebalanced pricing transparency to 25%.
v2.5 (Feb 2026) — Added pharmacy disclosure (503A/503B) as required signal.
v2.0 (Oct 2025) — Initial 5-dimension rubric with weights.

Questions about methodology: [email protected]

Primary sources reviewed

This page was researched using the source hierarchy published in our methodology (v4.0):

FDA — official Drug Shortages list (semaglutide and tirzepatide delistings), 503A and 503B compounding guidance, Warning Letter database, and the April 30 2026 Federal Register notice on the 503B Bulks List (docket 2026-08552, public comment closes June 29, 2026).
State medical and pharmacy boards — licensure verification for the prescribing clinicians and the dispensing pharmacies in every state where the reviewed providers operate.
Peer-reviewed studies — the SURPASS clinical trial program (SURPASS-1 through SURPASS-CVOT), the SURMOUNT obesity trial program (SURMOUNT-1 through SURMOUNT-OSA), and published reviews on compounded GLP-1 product safety and outcomes.
Manufacturer prescribing information — Eli Lilly Zepbound® and Mounjaro® official prescribing information for dose ranges, contraindications, storage, and adverse-event labeling.
Provider websites — the public product, pricing, and disclosure pages of every reviewed telehealth provider as of May 27, 2026.
Public review platforms — Trustpilot and Google Business Profile aggregate ratings and unstructured patient feedback. Ratings were retrieved May 27, 2026 and may change over time.

Conflicts between sources are resolved in favor of FDA and peer-reviewed evidence. Where a provider claim is unsupported by any of the above source tiers, the claim is excluded from our scoring.

Important context & disclosures

Brand-name option is appropriate for many patients. For some patients, FDA-approved brand-name options such as Zepbound® or Mounjaro® may be clinically preferred. Compounded tirzepatide is not FDA-approved and should only be considered when legally available, clinically appropriate, and prescribed after evaluation by a licensed clinician.

Pricing notes

Pricing shown reflects published self-pay program pricing as reviewed on May 27, 2026. Monthly equivalent pricing may vary by plan length. Always confirm current pricing on the provider’s official website. NexLife: from $186/month with a 12-month plan.

State availability

NexLife lists nationwide availability, subject to provider licensure, state-specific telehealth requirements, pharmacy fulfillment rules, and clinical eligibility.

Pharmacy partners

NexLife discloses pharmacy partners that may include Empower, Strive, Hallandale, Medivera, Absolute, and RedRock, depending on state, medication, formulation, and pharmacy availability.

Ratings and reviews

Trustpilot rating retrieved May 27, 2026. Ratings may change over time.

Suggested citation

TirzepatideReview.com (Ronika Partners LLC). “Editorial Standards.” Reviewed May 27, 2026. Retrieved from https://tirzepatidereview.com/editorial-standards.html.